Amneal Pharmaceuticals (NYSE:AMRX) Stock Price Down 4.3%

Amneal Pharmaceuticals Inc (NYSE:AMRX) shares were down 4.3% on Thursday . The company traded as low as $2.56 and last traded at $2.46, approximately 24,520 shares changed hands during mid-day trading. A decline of 99% from the average daily volume of 2,522,662 shares. The stock had previously closed at $2.57.

A number of equities research analysts recently weighed in on AMRX shares. Raymond James lowered shares of Amneal Pharmaceuticals from a “strong-buy” rating to an “outperform” rating and lowered their target price for the stock from $13.00 to $8.50 in a report on Wednesday, July 10th. BMO Capital Markets lowered their target price on shares of Amneal Pharmaceuticals from $6.00 to $5.00 and set a “market perform” rating on the stock in a report on Tuesday, August 6th. ValuEngine upgraded shares of Amneal Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Tuesday, May 7th. Leerink Swann upgraded shares of Amneal Pharmaceuticals from a “market perform” rating to an “outperform” rating in a report on Monday, July 22nd. Finally, Barclays set a $5.00 target price on shares of Amneal Pharmaceuticals and gave the stock a “hold” rating in a report on Thursday, July 11th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and seven have assigned a buy rating to the company. Amneal Pharmaceuticals has a consensus rating of “Hold” and an average price target of $12.13.

The company has a debt-to-equity ratio of 3.66, a quick ratio of 1.41 and a current ratio of 2.17. The stock has a market cap of $849.42 million, a PE ratio of 2.53, a price-to-earnings-growth ratio of 0.35 and a beta of 1.41. The company’s 50 day simple moving average is $4.30 and its 200 day simple moving average is $9.69.

Amneal Pharmaceuticals (NYSE:AMRX) last posted its quarterly earnings data on Monday, August 5th. The company reported $0.09 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.14 by ($0.05). The firm had revenue of $404.60 million during the quarter, compared to analysts’ expectations of $420.12 million. Amneal Pharmaceuticals had a negative net margin of 3.65% and a positive return on equity of 28.20%. The company’s quarterly revenue was down 12.5% on a year-over-year basis. During the same quarter last year, the business posted $0.24 EPS. Equities research analysts expect that Amneal Pharmaceuticals Inc will post 0.51 earnings per share for the current year.

In other news, major shareholder International Ltd Fosun acquired 1,642,300 shares of the firm’s stock in a transaction on Monday, August 5th. The stock was purchased at an average price of $3.04 per share, for a total transaction of $4,992,592.00. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Andrew S. Boyer acquired 66,666 shares of the firm’s stock in a transaction on Wednesday, August 7th. The stock was purchased at an average price of $2.89 per share, with a total value of $192,664.74. The disclosure for this purchase can be found here. Company insiders own 26.34% of the company’s stock.

Large investors have recently bought and sold shares of the business. New York State Common Retirement Fund increased its stake in Amneal Pharmaceuticals by 27.3% in the 1st quarter. New York State Common Retirement Fund now owns 108,616 shares of the company’s stock valued at $1,539,000 after buying an additional 23,316 shares during the last quarter. Meeder Asset Management Inc. grew its position in shares of Amneal Pharmaceuticals by 785.6% during the 1st quarter. Meeder Asset Management Inc. now owns 11,664 shares of the company’s stock valued at $166,000 after acquiring an additional 10,347 shares during the period. Norges Bank bought a new position in shares of Amneal Pharmaceuticals during the 4th quarter valued at approximately $18,243,000. Principal Financial Group Inc. grew its position in shares of Amneal Pharmaceuticals by 30.4% during the 4th quarter. Principal Financial Group Inc. now owns 16,485 shares of the company’s stock valued at $223,000 after acquiring an additional 3,843 shares during the period. Finally, Brinker Capital Inc. grew its position in shares of Amneal Pharmaceuticals by 11.1% during the 1st quarter. Brinker Capital Inc. now owns 21,110 shares of the company’s stock valued at $299,000 after acquiring an additional 2,105 shares during the period. Hedge funds and other institutional investors own 34.63% of the company’s stock.

Amneal Pharmaceuticals Company Profile (NYSE:AMRX)

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.

Featured Story: Golden Cross

Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.